J.P. Morgan starts Seres at neutral on c. difficile asset
J.P. Morgan has initiated Seres Therapeutics (MCRB) with a neutral rating saying that it will take time for SER-109 to have its reimbursement take place.
Bacterial Consortium Therapy for Prevention of Recurrent C difficile Infection
This clinical trial compares the efficacy of 2 different doses of VE303, a defined bacterial consortium of 8 strains of commensal Clostridia, and placebo in preventing recurrence of Clostridioides difficile infection among adults at high risk.
Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference | MarketScreener
A scientific poster highlighting a novel pharmacologic property of oral ibezapolstat for C. difficile Infection likely related to its unique mechanism of action was presented at ECCMID 2023An update... | April 19, 2023
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License Agreement | MarketScreener
SOMERVILLE, Mass., April 18, 2023 -- Finch Therapeutics Group, Inc. , a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has... | April 18, 2023
PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID | MarketScreener
JAMA publication includes in-depth safety and efficacy results from Vedanta’s successful Phase 2 study of VE303
... | April 17, 2023
Bacterial consortium therapy for prevention of recurrent c difficile infection
About The Study: Among adults with laboratory-confirmed Clostridioides difficile infection (CDI) with one or more prior CDI episodes in the last six months and those with primary CDI at high risk for recurrence, high-dose VE303 (a novel oral microbiome-directed therapy composed of nonpathogenic, nontoxigenic, commensal strains of Clostridia) prevented recurrent CDI compared with placebo. A larger, phase 3 study is needed to confirm these findings.
CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against Clostridioides difficile Infection and Recurrence in Mouse and Hamster Infection Models - PubMed
Clostridioides difficile infection (CDI) causes severe diarrhea and colitis, leading to significant morbidity, mortality, and high medical costs worldwide. Oral vancomycin, a first-line treatment for CDI, is associated with a high risk of recurrence, necessitating novel therapies for primary and rec …
FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference | BioSpace
FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference - read this article along with other careers information, tips and advice on BioSpace
Global C DIFFICILE INFECTION DRUG Market Analysis And Trend By Segmentations, Top Key Players, Geographical Expansion, Future Development & Forecast 2023-2032
Market Tree Research has added a new key research reports covering C DIFFICILE INFECTION DRUG market The study aims to provide global investors with a game changing decision making tool covering key fundamentals of the C DIFFICILE INFECTION DRUG market ...
Clostridium difficile Infection Market to Show Immense Growth at a CAGR of 12.5% During the Study Period (2019-2032) | Major Companies- Pfizer, Valneva, GlaxoSmithKline, and Others
Designer bacteria PROT3ECTs against inflammation in IBD mouse model
A team of researchers from Harvard University has developed a suite of Escherichia coli Nissle 1917 (EcN), named PRObiotic type 3 secretion E. coli therapeutic (PROT3ECT), engineered to secrete a TNF-α nanobody directly into the gut to reduce inflammation in a chemically induced inflammatory bowel disease (IBD) mouse model.
Destiny Pharma hails latest peer-reviewed research on CDI asset
Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) said data from a study on one of its lead assets has been peer-reviewed and published in Microbiology Spectrum. A...
Engineered E. coli delivers therapeutic nanobodies to the gut
Researchers have succeeded in developing an E. coli-based 'smart microbe' that secretes therapeutic payloads, including antibodies, into the gut. The genetically modified beneficial strain of bacteria blocks intestinal inflammation in a preclinical model of inflammatory bowel disease and has the potential to treat intestinal-based diseases.
Intermountain study warns of harms from unnecessary antibiotic use
A new study by researchers at Intermountain Health and Stanford University found that overprescribing and inappropriate prescribing of antibiotics is not only leading to antibiotic resistance, but also causing significant patient harm. Dr. Harris Carmichael, lead investigator of the study and a hospitalist at Intermountain Health, said the study, published in the Journal of Internal […]
Difficile Infections (Clostridium Difficile Associated Disease) Market is expected to be worth US$ 1,448.75 million by 2033 | FMI – Market Research Blog
Seres one step closer to bringing first oral microbiome therapy to market as FDA mulls approval
Seres Therapeutics’ SER-109 has faced more setbacks than most drugs, but the biotech has kept the faith and is now tantalizingly close to possibly seeing its candidate
Scientists make critical progress toward preventing C. diff infections
A new study has identified a compound that prevents C. diff infection. Researchers are now using this compound to develop new drug candidates that might eventually offer a way to prevent serious C. diff infections.
Bile salt analog prevents C. diff infection in mice, advancing work to stop killer bacterium
A bile salt analog prevented Clostridioides difficile infection (CDI) in mice, pointing to a potential way to minimize the impact of a bacterium that kills 20,000 people a year.
Discovery of Hippo signaling as a regulator of CSPG4 expression and as a therapeutic target for Clostridioides difficile disease - PubMed
The signaling pathways and networks regulating expression of chondroitin sulfate proteoglycan 4 (CSPG4), a cancer-related protein that serves as a receptor for Clostridiodes difficile TcdB, are poorly defined. In this study, TcdB-resistant/CSPG4-negative HeLa cells were generated by exposure to incr …
Preventative compound that prevents C. diff infection identified
Researchers at the University of Nevada, Las Vegas have identified a compound that prevents gastrointestinal infections from multiple strains of Chlostridiodes difficile (C. diff)—including those that can cause serious illness—and are now using the compound to develop drugs that could eventually prevent serious C. diff infections.
New drug could help 500,000 gastrointestinal patients in the US
Researchers have identified a compound that prevents C. diff infection caused by multiple strains of the bacterium and are using it to develop new drug candidates that target the disease.
Clostridioides Difficile Infection Treatment Market Size to be Steady at 1,447.0 Mn | Service Offered, Future prospects, Trend and Forecast by 2030 | Novartis AG, Baxter, ANI Pharmaceuticals, Inc., Mylan N.V., Akorn